Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Biohaven Faces Setback in Depression Treatment, Shifts Focus to Epilepsy

Biohaven Pharmaceuticals has encountered another significant obstacle in its drug development pipeline, as its potassium channel agonist BHV-7000 (opakalim) failed to demonstrate efficacy in a Phase II proof-of-concept study for major depressive disorder (MDD). This setback follows closely on the heels of a key FDA rejection in November 2025, painting a challenging picture for the company's psychiatric drug development efforts.

NoahAI News1/3/2026

Promising New Approach to Alzheimer's Treatment Shows Cognitive Restoration in Mice

A groundbreaking study from Case Western Reserve University has revealed a potential new avenue for treating Alzheimer's disease, offering hope for patients with advanced stages of the condition. Researchers have successfully demonstrated that restoring cellular energy levels can reverse cognitive decline in mouse models of Alzheimer's, potentially paving the way for a novel class of therapeutics.

NoahAI News1/3/2026

FDA Approves New Treatments for Thalassemia and Motion Sickness

The U.S. Food and Drug Administration (FDA) has ended 2025 with two significant approvals, granting the green light to Agios Pharmaceuticals' Aqvesme for thalassemia and Vanda Pharmaceuticals' Nereus for motion sickness. These approvals mark important milestones in their respective therapeutic areas, offering new options for patients and expanding the companies' product portfolios.

NoahAI News1/3/2026

Foresee Pharmaceuticals' Camcevi Shows Promise in Rare Pediatric Condition

Foresee Pharmaceuticals has announced positive results from a phase 3 study of its prostate cancer medication Camcevi in children with central precocious puberty (CPP), potentially expanding the drug's therapeutic applications.The Taiwan-based company's phase 3 Casppian study evaluated a 42 mg dose of leuprolide mesylate (FP-001), administered every six months. The primary endpoint focused on serum luteinizing hormone (LH) suppression, with 94% of patients achieving LH levels below 4 mIU/mL at 60 minutes after GnRHa stimulation at week 24. This statistically significant result exceeded the pre-specified criteria for success.

NoahAI News1/3/2026

Nido Biosciences Shuts Down Following Phase 2 Trial Disappointment in Kennedy's Disease

Nido Biosciences, a promising neuro-focused biotech startup, has announced its closure after a disappointing phase 2 clinical trial for its lead candidate targeting Kennedy's disease. The company, which emerged in 2023 with substantial financial backing, will wind down operations in early 2026, marking a setback in the pursuit of treatments for rare neurological disorders.

NoahAI News1/3/2026

Verastem Shifts Focus from KRAS G12C to G12D in NSCLC, Discontinues Phase 1/2 Trial

Verastem Oncology has announced a strategic pivot in its non-small cell lung cancer (NSCLC) program, discontinuing its phase 1/2 trial targeting KRAS G12C mutations and redirecting resources towards the development of VS-7375, an oral KRAS G12D inhibitor. This decision comes in the wake of emerging next-generation KRAS G12C inhibitors that have set new benchmarks for efficacy in the field.

NoahAI News1/3/2026

InflaRx Revives Hope for Vilobelimab in Pyoderma Gangrenosum, Seeks Partner for Development

German pharmaceutical company InflaRx has announced renewed interest in its C5a antibody vilobelimab for the treatment of pyoderma gangrenosum (PG), a rare skin disorder. This development comes after the company's initial decision to terminate a phase 3 trial in May 2025 due to futility. Post hoc analyses of the terminated study have revealed promising trends, prompting InflaRx to consider reviving the drug's development in collaboration with a partner.

NoahAI News1/3/2026

AbbVie, Gilead, and ASK Pharm Secure New Cancer Drug Candidates in Year-End Deals

Major pharmaceutical companies AbbVie and Gilead Sciences, along with Chinese firm ASK Pharm, have closed out the year by acquiring rights to promising cancer drug candidates, signaling continued investment in oncology research and development.AbbVie has entered into an agreement with Zejing Biopharmaceutical for the option to license alveltamig (ZG006), a DLL3-targeting trispecific T-cell binder, outside of China. The deal includes a $100 million upfront payment, with potential for an additional $60 million if AbbVie exercises its option, and milestone payments that could reach $1.07 billion.

NoahAI News1/3/2026

J&J and Genmab Discontinue Key Therapies Amid Strategic Shifts

Johnson & Johnson and Genmab have both announced the termination of high-profile drug development programs, signaling significant shifts in their respective pipelines as the pharmaceutical industry enters 2026.Johnson & Johnson has ceased development of JNJ-95475939, an IL-4 and IL-31 inhibitor acquired from Numab Therapeutics in 2024 for $1.25 billion. The drug, aimed at treating moderate to severe atopic dermatitis, failed to meet efficacy expectations in a phase 2b study comparing it to Dupixent, a leading IL-4 and IL-13 inhibitor.

NoahAI News1/3/2026

NIH Leadership Crisis Deepens as NINDS Director Departs

The National Institutes of Health (NIH) is facing a growing leadership crisis as Walter Koroshetz, M.D., director of the National Institute of Neurological Disorders and Stroke (NINDS), becomes the latest high-profile departure from the agency. This exit, slated for January 24, 2026, marks a significant blow to the stability of the NIH, leaving more than half of its institutes under interim leadership.

NoahAI News1/3/2026

Ultragenyx Faces Setback as Bone Disease Trials Fail to Meet Primary Endpoint

Ultragenyx Pharmaceutical has reported disappointing results from two late-phase clinical trials for setrusumab, a sclerostin-inhibiting antibody developed to treat osteogenesis imperfecta, commonly known as brittle bone disease. The failure of these trials has prompted the company to announce plans for significant cost-cutting measures and has sent ripples through the biotech industry.

NoahAI News1/2/2026

Pharma M&A Heats Up: 2025 Sees Record-Breaking Deals and Fierce Bidding Wars

The pharmaceutical industry witnessed a resurgence in mergers and acquisitions (M&A) activity in 2025, with several multibillion-dollar deals shaping the landscape. After a post-pandemic lull, Big Pharma flexed its financial muscle, engaging in high-stakes bidding wars and strategic acquisitions to bolster pipelines and secure future revenue streams.

NoahAI News1/2/2026

1 2 3 4...67 »